Cannabis (THC vs. CBD) in Multiple Sclerosis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Sclerosis
Interventions
DRUG

THC

Participants will be randomly assigned to the study treatment. THC dose will be gradually increased until 25 mg. Treatment will be taken orally at bedtime for 15 weeks.

DRUG

CBD

Participants will be randomly assigned to the study treatment. CBD dose will be gradually increased until 50 mg. Treatment will be taken orally at bedtime for 15 weeks.

All Listed Sponsors
collaborator

Multiple Sclerosis Society of Canada

OTHER

lead

University of Calgary

OTHER